↓ Skip to main content

Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer';s Disease

Overview of attention for article published in Current Topics in Medicinal Chemistry, April 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#10 of 1,366)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
2 news outlets
blogs
2 blogs
twitter
5 tweeters
facebook
4 Facebook pages

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer';s Disease
Published in
Current Topics in Medicinal Chemistry, April 2016
DOI 10.2174/1568026616666160204121431
Pubmed ID
Authors

Nady Braidy, Bat-Erdene Jugder, Anne Poljak, Tharusha Jayasena, Hussein Mansour, Seyed Mohammad Nabavi, Perminder Sachdev, Ross Grant

Abstract

Resveratrol (3,4',5-trihydroxystilbene) is a naturally occurring polyphenolic compound present in over 70 different plant-derived products, including red wine, grapes, berries, chocolate and peanuts. Clinically, resveratrol demonstrates strong antioxidant, anti-inflammatory, anti-viral, and anti-cancer properties. Although resveratrol was first isolated in 1940, it was not until the last decade that it was recognised for its potential therapeutic role in reducing the risk of neurodegenerative disorders, and Alzheimer's disease (AD) in particular. AD is the leading cause of progressive dementia, in the elderly. Resveratrol has been shown to exhibit neuroprotective effects in a variety of in vitro and in vivo models of AD. Apart from its potent antioxidant and anti-inflammatory roles, evidence suggests that resveratrol also facilitates non-amyloidogenic cleavage of the amyloid precursor protein (APP), and promotes clearance of neurotoxic amyloid beta (Aβ) peptides, a critical step in preventing and slowing down AD pathology. Resveratrol also reduces damage to neuronal cells via a variety of additional mechanisms, most notably is the activation of a new class of NAD+-dependent histone deacetylases enzymes known as sirtuins. However in spite of the considerable advances in defining the mechanism of action of resveratrol, it is unlikely to be effective as monotherapy in AD due to its poor bioavailability, biotransformation, and requisite synergism with other dietary factors. This review summarizes the relevance of resveratrol in the pathophysiology of AD. It also highlights why resveratrol alone may not be an effective single therapy, and how resveratrol coupled to other compounds might yet prove an effective therapy with multiple targets.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 17%
Student > Ph. D. Student 7 17%
Researcher 5 12%
Student > Master 4 10%
Student > Doctoral Student 3 7%
Other 7 17%
Unknown 9 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 14%
Agricultural and Biological Sciences 4 10%
Neuroscience 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Chemistry 3 7%
Other 7 17%
Unknown 15 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2021.
All research outputs
#709,446
of 17,424,044 outputs
Outputs from Current Topics in Medicinal Chemistry
#10
of 1,366 outputs
Outputs of similar age
#17,401
of 349,689 outputs
Outputs of similar age from Current Topics in Medicinal Chemistry
#1
of 38 outputs
Altmetric has tracked 17,424,044 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,366 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,689 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.